TW201936189A - 用於使用fxr激動劑之方法 - Google Patents

用於使用fxr激動劑之方法 Download PDF

Info

Publication number
TW201936189A
TW201936189A TW107142391A TW107142391A TW201936189A TW 201936189 A TW201936189 A TW 201936189A TW 107142391 A TW107142391 A TW 107142391A TW 107142391 A TW107142391 A TW 107142391A TW 201936189 A TW201936189 A TW 201936189A
Authority
TW
Taiwan
Prior art keywords
tropine
dose
liver
nash
treatment
Prior art date
Application number
TW107142391A
Other languages
English (en)
Chinese (zh)
Inventor
麥克 巴德曼
克里夫 布瑞斯
布萊恩 拉菲特
Original Assignee
瑞士商諾華公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商諾華公司 filed Critical 瑞士商諾華公司
Publication of TW201936189A publication Critical patent/TW201936189A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW107142391A 2017-11-30 2018-11-28 用於使用fxr激動劑之方法 TW201936189A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762593084P 2017-11-30 2017-11-30
US62/593,084 2017-11-30

Publications (1)

Publication Number Publication Date
TW201936189A true TW201936189A (zh) 2019-09-16

Family

ID=64959384

Family Applications (1)

Application Number Title Priority Date Filing Date
TW107142391A TW201936189A (zh) 2017-11-30 2018-11-28 用於使用fxr激動劑之方法

Country Status (12)

Country Link
US (2) US20210361638A1 (cg-RX-API-DMAC7.html)
EP (1) EP3716977A1 (cg-RX-API-DMAC7.html)
JP (1) JP2021504370A (cg-RX-API-DMAC7.html)
KR (1) KR20200094175A (cg-RX-API-DMAC7.html)
CN (1) CN111356458A (cg-RX-API-DMAC7.html)
AU (1) AU2018376904B2 (cg-RX-API-DMAC7.html)
CA (1) CA3081656A1 (cg-RX-API-DMAC7.html)
IL (1) IL274747A (cg-RX-API-DMAC7.html)
MX (1) MX2020005557A (cg-RX-API-DMAC7.html)
RU (1) RU2020121222A (cg-RX-API-DMAC7.html)
TW (1) TW201936189A (cg-RX-API-DMAC7.html)
WO (1) WO2019106550A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021014349A1 (en) * 2019-07-23 2021-01-28 Novartis Ag Treatment comprising fxr agonists
CN114502198A (zh) * 2019-09-30 2022-05-13 诺华股份有限公司 包括使用fxr激动剂的治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005089316A2 (en) * 2004-03-12 2005-09-29 Intercept Pharmaceuticals, Inc. Treatment of fibrosis using fxr ligands
CU24152B1 (es) 2010-12-20 2016-02-29 Irm Llc 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr
LT3419625T (lt) 2016-02-22 2021-07-26 Novartis Ag Fxr agonistų panaudojimo būdai
HK1257648A1 (zh) * 2016-02-22 2019-10-25 Novartis Ag Fxr促效剂之使用方法
SI3419624T1 (sl) * 2016-02-22 2021-05-31 Novartis Ag Postopki za uporabo agonistov FXR
AR114930A1 (es) * 2017-09-12 2020-11-11 Novartis Ag Composición farmacéutica

Also Published As

Publication number Publication date
IL274747A (en) 2020-07-30
CA3081656A1 (en) 2019-06-06
EP3716977A1 (en) 2020-10-07
US20190161483A1 (en) 2019-05-30
AU2018376904B2 (en) 2021-07-22
KR20200094175A (ko) 2020-08-06
US20210361638A1 (en) 2021-11-25
CN111356458A (zh) 2020-06-30
RU2020121222A (ru) 2021-12-30
RU2020121222A3 (cg-RX-API-DMAC7.html) 2022-04-19
MX2020005557A (es) 2020-08-20
AU2018376904A1 (en) 2020-05-21
WO2019106550A1 (en) 2019-06-06
JP2021504370A (ja) 2021-02-15

Similar Documents

Publication Publication Date Title
US11517572B2 (en) Killing senescent cells and treating senescence-associated conditions using a SRC inhibitor and a flavonoid
TWI735546B (zh) 使用fxr促效劑之方法
Fucho et al. ASMase regulates autophagy and lysosomal membrane permeabilization and its inhibition prevents early stage non-alcoholic steatohepatitis
AU2020203316B2 (en) Novel regimes of FXR agonists
Sims-Robinson et al. The role of endoplasmic reticulum stress in hippocampal insulin resistance
TW201735923A (zh) 使用fxr促效劑之方法
EP3681537A1 (en) Combinations comprising fxr agonists
JP2019530696A (ja) 線維性、硬変性の疾患もしくは障害を治療または予防するためのfxrアゴニストを含む組合せ組成物
Mai et al. Silibinin ameliorates deoxycholic acid-induced pyroptosis in steatotic HepG2 cells by inhibiting NLRP3 inflammasome activation
Yoo et al. DA-1241, a GPR119 agonist, ameliorates fatty liver through the upregulation of TFEB-mediated autophagy
Hossain et al. KIT-13, a novel plasmalogen derivative, attenuates neuroinflammation and amplifies cognition
TW202114654A (zh) 包含如sglt 1/2抑制劑的sglt抑制劑之治療
TWI906348B (zh) 脂肪性肝疾病之治療劑
AU2018376904B2 (en) FXR agonists for the treatment of liver diseases
Barbut et al. Anti-aging properties of the aminosterols of the dogfish shark
JP2022550312A (ja) Fxrアゴニストの使用を含む処置
CN111225666A (zh) 用于治疗、预防或改善肝纤维化的γ-酮醛清除剂的组合物和使用方法
JP2019524860A (ja) 非アルコール性脂肪肝疾患の治療法